Jacobio Starts Trial of SHP2 Inhibitor, Triggering $20 Million Payment from AbbVie
publication date: Jun 18, 2021
Beijing Jacobio Pharma has dosed the first two patients in a Phase I/IIa trial of its SHP2 inhibitor in patients with solid tumor cancers. One year ago, Jacobio out-licensed global rights for two small molecule SHP2 inhibitors to AbbVie. AbbVie made a $45 million upfront payment to Jacobio, and the start of the trial triggers a $20 million milestone payment from AbbVie. The SHP2 inhibitor, JAB-3312, will be administered in combination with PD-1 antibody pembrolizumab and MEK inhibitor binimetinib. More details....
Stock Symbols: (HK: 1167) (NYSE: ABBV)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.